Krystal Biotech, Inc. (NASDAQ:KRYS) Receives $211.13 Consensus Price Target from Analysts
Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) have received an average recommendation of “Buy” from the nine analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on […]
Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Free Report) have received an average recommendation of “Buy” from the nine analysts that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating on […]
